Conservest Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Conservest Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.39M	Sell	27,770 -3,483	-11%	-$471K	0.35%	34
2026 Q1	$3.99M	Buy	31,253 +1,139	+4%	+$142K	0.36%	33
2025 Q4	$3.67M	Buy	30,114 +972	+3%	+$111K	0.33%	31
2025 Q3	$2.92M	Buy	29,142 +478	+2%	+$43.1K	0.27%	31
2025 Q2	$2.38M	Sell	28,664 -2,910	-9%	-$232K	0.23%	35
2025 Q1	$2.56M	Sell	31,574 -589	-2%	-$52.6K	0.27%	33
2024 Q4	$2.9M	Sell	32,163 -8,650	-21%	-$838K	0.3%	30
2024 Q3	$3.87M	Buy	40,813 +7,772	+24%	+$764K	0.4%	26
2024 Q2	$3.14M	Sell	33,041 -7,772	-19%	-$697K	0.34%	31
2024 Q1	$3.87M	Buy	40,813 +1,822	+5%	+$169K	0.4%	26
2023 Q4	$3.48M	Buy	38,991 +912	+2%	+$67.7K	0.37%	29
2023 Q3	$2.78M	Buy	38,079 +3,151	+9%	+$252K	0.34%	30
2023 Q2	$2.91M	Buy	34,928 +914	+3%	+$76.4K	0.34%	30
2023 Q1	$2.59M	Buy	34,014 +232	+0.7%	+$19.3K	0.31%	30
2022 Q4	$2.8M	Buy	+33,782	New	+$2.73M	0.36%	29
2022 Q3	–	Sell	-27,496	Closed	-$2.32M	–	30
2022 Q2	$2.04M	Buy	27,496 +14,876	+118%	+$1.12M	0.25%	33
2022 Q1	$1.13M	Buy	12,620 +5,320	+73%	+$491K	0.13%	38
2021 Q4	$817K	Sell	7,300 -12,093	-62%	-$1.46M	0.09%	52
2021 Q3	$2.44M	Buy	19,393 +3,837	+25%	+$494K	0.27%	29
2021 Q2	$2.11M	Buy	15,556 +4,633	+42%	+$609K	0.24%	32
2021 Q1	$1.48M	Buy	10,923 +2,704	+33%	+$405K	0.17%	34
2020 Q4	$1.16M	Buy	8,219 +3,436	+72%	+$440K	0.14%	40
2020 Q3	$533K	Buy	+4,783	New	+$536K	0.07%	48

Other funds holding XBI

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

Conservest Capital Advisors's XBI Position: Q2 2026 in Review

Conservest Capital Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q2 2026, selling an estimated $471K and leaving 27,770 shares worth $4.39M. The position accounts for 0.35% of the portfolio, ranked #34.

Conservest Capital Advisors first reported a position in XBI in Q3 2020 and has held it in 23 quarters since. 393 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Conservest Capital Advisors held 27,770 shares of State Street SPDR S&P Biotech ETF worth $4.39M as of Q2 2026.
Conservest Capital Advisors sold 3,483 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $471K.
State Street SPDR S&P Biotech ETF made up 0.35% of Conservest Capital Advisors's portfolio in Q2 2026, its #34 holding.
Conservest Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 23 quarters since.
393 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Conservest Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.